3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
18
Breast
8
Gynecologic
6
Thoracic
5
Tumor-Agnostic
3
Genitourinary
2
Plasma cell
1
Other solid neoplasm
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Conditions
Multiple Endocrine Neoplasia Type 1
1
Hypertension
1
Colonic Neoplasms
1
Interventions
Everolimus
32
Octreotide
15
Cisplatin
14
pasireotide
13
Sunitinib
13
Temozolomide
11
pembrolizumab
10
Etoposide
10
Doxorubicin
10
lanreotide
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
9
lutetium Lu 177 dotatate
8
gallium Ga 68 dotatate
8
Sorafenib
8
Paclitaxel
8
3-Iodobenzylguanidine
8
lenvatinib
7
pazopanib
6
Radiotherapy
6
Positron Emission Tomography Computed Tomography
6
Nivolumab
6
surufatinib
5
cabozantinib
5
avelumab
5
Thyrotropin Alfa
5
Surgical Procedures, Operative
5
Radiosurgery
5
Mitotane
5
Irinotecan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Navigation
×
Endocrine
×
Clear all
NCT01092078
2015-04-22
MISTER-B
NYU Langone Health
Phase NA
Completed
740 enrolled